Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors.
Yun-Ting ZhuZan TengYi-Fan ZhangWei LiLi-Xia GuoYun-Peng LiuXiu-Juan QuQuan-Ren WangSi-Yuan MaoXiao-Yan ChenDa-Fang ZhongPublished in: Drug design, development and therapy (2020)
Concomitant apatinib administration resulted in significant increases in systemic exposure to nifedipine and S-warfarin. Owing to the risk of pharmacokinetic drug-drug interactions based on CYP3A4/CYP2C9 inhibition by apatinib, caution is advised in the concurrent use of apatinib with either CYP2C9 or CYP3A4 substrates.